M. Kulyk & Associates LLC Decreases Stake in Merck & Co., Inc. $MRK

M. Kulyk & Associates LLC decreased its holdings in Merck & Co., Inc. (NYSE:MRK) by 3.4% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 94,863 shares of the company’s stock after selling 3,331 shares during the quarter. Merck & Co., Inc. comprises approximately 2.0% of M. Kulyk & Associates LLC’s portfolio, making the stock its 12th biggest holding. M. Kulyk & Associates LLC’s holdings in Merck & Co., Inc. were worth $12,190,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently bought and sold shares of MRK. Kingdom Financial Group LLC. acquired a new position in shares of Merck & Co., Inc. during the 4th quarter worth $25,000. Abound Financial LLC acquired a new stake in shares of Merck & Co., Inc. in the fourth quarter valued at about $26,000. Prosperity Bancshares Inc acquired a new stake in shares of Merck & Co., Inc. in the fourth quarter valued at about $26,000. High Note Wealth LLC boosted its holdings in Merck & Co., Inc. by 58.9% during the fourth quarter. High Note Wealth LLC now owns 294 shares of the company’s stock worth $31,000 after buying an additional 109 shares in the last quarter. Finally, IFC & Insurance Marketing Inc. acquired a new position in Merck & Co., Inc. during the fourth quarter worth about $31,000. Institutional investors and hedge funds own 76.07% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have issued reports on MRK. Daiwa Securities Group raised shares of Merck & Co., Inc. from a “neutral” rating to an “outperform” rating and set a $143.00 target price for the company in a report on Wednesday, August 12th. Scotiabank upped their price target on Merck & Co., Inc. from $136.00 to $155.00 and gave the stock a “sector outperform” rating in a report on Tuesday, June 30th. Royal Bank Of Canada downgraded Merck & Co., Inc. from an “outperform” rating to a “sector perform” rating and raised their price objective for the company from $142.00 to $150.00 in a research note on Thursday, August 20th. UBS Group lifted their price objective on Merck & Co., Inc. from $145.00 to $175.00 and gave the stock a “buy” rating in a report on Thursday, August 20th. Finally, JPMorgan Chase & Co. boosted their target price on Merck & Co., Inc. from $135.00 to $140.00 and gave the stock an “overweight” rating in a research report on Monday, July 13th. Fifteen research analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the stock. Based on data from MarketBeat, Merck & Co., Inc. currently has an average rating of “Moderate Buy” and an average price target of $147.60.

Insider Activity

In other Merck & Co., Inc. news, EVP Richard R. Deluca sold 11,699 shares of the firm’s stock in a transaction on Wednesday, August 12th. The stock was sold at an average price of $131.63, for a total transaction of $1,539,939.37. Following the completion of the transaction, the executive vice president owned 110,167 shares of the company’s stock, valued at approximately $14,501,282.21. This trade represents a 9.60% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP David Michael Williams sold 52,847 shares of the business’s stock in a transaction on Wednesday, August 5th. The stock was sold at an average price of $128.77, for a total value of $6,805,108.19. Following the completion of the transaction, the executive vice president directly owned 31,716 shares of the company’s stock, valued at approximately $4,084,069.32. This trade represents a 62.49% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 228,238 shares of company stock worth $29,977,783 in the last quarter. 0.17% of the stock is currently owned by corporate insiders.

Merck & Co., Inc. Stock Performance

Shares of MRK opened at $153.21 on Thursday. The company has a current ratio of 1.32, a quick ratio of 1.10 and a debt-to-equity ratio of 1.22. The stock has a market cap of $378.00 billion, a P/E ratio of 122.57, a PEG ratio of 6.56 and a beta of 0.19. The company has a 50-day moving average of $130.39 and a two-hundred day moving average of $122.04. Merck & Co., Inc. has a 12-month low of $77.58 and a 12-month high of $156.92.

Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings results on Tuesday, August 4th. The company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.26) by $0.13. Merck & Co., Inc. had a net margin of 4.77% and a return on equity of 16.73%. The business had revenue of $16.61 billion for the quarter, compared to analyst estimates of $16.37 billion. During the same period in the prior year, the business earned $2.13 earnings per share. The company’s quarterly revenue was up 5.1% on a year-over-year basis. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. As a group, research analysts predict that Merck & Co., Inc. will post 2.76 EPS for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, October 7th. Shareholders of record on Tuesday, September 15th will be issued a dividend of $0.85 per share. This represents a $3.40 dividend on an annualized basis and a yield of 2.2%. The ex-dividend date is Tuesday, September 15th. Merck & Co., Inc.’s dividend payout ratio is 272.00%.

Key Stories Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Positive melanoma results strengthen the pipeline. Merck and Moderna reported positive Phase 3 topline results for intismeran autogene, an individualized neoantigen therapy used with KEYTRUDA in resected melanoma. The program could create a new growth opportunity and help extend KEYTRUDA’s commercial runway. Merck Surges on a Melanoma Win
• Positive Sentiment: A busy fall catalyst calendar is attracting investors. Upcoming FDA decisions, additional pipeline updates and a pivotal cancer-vaccine readout could materially influence expectations for Merck’s post-KEYTRUDA growth profile. What Would It Take to Get MRK Stock to $200?
• Positive Sentiment: Pipeline progress, new product launches and potential M&A are improving the long-term growth outlook and easing concerns about eventual KEYTRUDA revenue pressure. Merck Stock Hits New 52-Week High
• Positive Sentiment: Analysts have become more bullish. Wolfe Research raised its price target from $155 to $180 with an outperform rating, while Argus increased its target from $145 to $170 and upgraded the stock to buy. These revisions provide additional support for the recent advance.
• Neutral Sentiment: The cancer-vaccine opportunity remains uncertain. Reuters noted that evidence for broad use of the personalized therapy is still limited, with manufacturing, patient-selection and clinical-adoption challenges potentially affecting its commercial impact. How the Merck-Moderna Cancer Vaccine Works
• Negative Sentiment: Valuation and execution risks are increasing. After gaining roughly 19% over the past month and trading near its 52-week high, MRK is approaching analyst targets, leaving less room for disappointment. Investors will likely focus on whether upcoming approvals and trial results can justify further upside.

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.